Bristol-Myers Squibb BMY · USD
Health Care · Pharmaceuticals · US listing · 🇺🇸 United States
S&P 500
62.14
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bristol-Myers Squibb
From its filings with the US Securities and Exchange Commission
Bristol-Myers Squibb is based in Princeton, New Jersey and is incorporated in Delaware. Its shares trade on NYSE under the ticker BMY. It is a member of the S&P 500. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $48.19bn and net income of $7.05bn. At that date it held total assets of $90.04bn and shareholders' equity of $18.47bn. By region, United States accounted for 69.1%, followed by International at 28.7% and Other at 2.3%.
Bristol-Myers Squibb Company ("we", the "Company", "Bristol Myers Squibb", or "BMS") was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger.
We compete with other global research-based drug companies, many smaller research companies with more limited therapeutic focus and generic drug manufacturers. Our products are sold worldwide, principally to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, government agencies and directly to patients. We have significant manufacturing operations in the U.S., Puerto Rico, the Netherlands, Ireland and Switzerland.
Our differentiated research platforms support long-term growth across therapeutic areas. Our platforms are comprised of chemically-synthesized or small molecule drugs including protein degraders, drugs produced from biological processes, called “biologics”, ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are also used. Biologics are typically administered through injections or by intravenous infusion. CAR-T cell therapies are administered by intravenous infusion.
Quoted from its 10-K, filed 11 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 5 Jul 1929
- Employees
- 32,500
- Website
- bms.com ↗
- Head office
- ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NJ, 08543
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Peter ArduiniIndependent Director$376,790
- Dr. Christopher BoernerChairman of the Board, Chief Executive Officer, since 2018$18.8m
- Mr. David ElkinsExecutive Vice President, Chief Financial Officer, Member of the Leadership Team$8.7m
- Mr. Benjamin HickeyPresident - RayzeBio Organization, Member of the Leadership Team
- Ms. Lynelle HochPresident, Cell Therapy Organization, Member of the Leadership Team
- Ms. Amanda PooleExecutive Vice President, Chief People Officer, Member of the Leadership Team
- Mr. Greg MeyersExecutive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team
- Ms. Cari GallmanExecutive Vice President, General Counsel and Chief Policy Officer
- Mr. Adam LenkowskyExecutive Vice President, Chief Commercialization Officer, Member of the Leadership Team
- Mr. Robert PlengeExecutive Vice President, Chief Research Officer, Head of Research, Member of the Leadership Team
- Ms. Karin ShanahanExecutive Vice President, Global Product Development & Supply, Member of the Leadership Team$6.6m
- Mr. Phil HolzerSenior Vice President, Controller
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 69
- Environment
- 79
- Social
- 82
- Governance
- 47
- Direct emissions (scope 1)
- 208,535 t
- Energy emissions (scope 2)
- 158,817 t
- Value chain emissions (scope 3)
- 1,750,947 t
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bristol-Myers Squibb Co has a strong product portfolio comprising innovative drugs and therapies.
- The company has established long-term partnerships with various leading healthcare organizations, fostering collaborations and knowledge sharing.
- Bristol-Myers Squibb Co has a robust research and development pipeline, which ensures a continuous flow of new products and potential revenue streams.
Weaknesses
- The company heavily relies on a few key products, which can pose a risk if any of those products face regulatory issues or patent expiration.
- Bristol-Myers Squibb Co has faced challenges in effectively managing supply chain operations, leading to disruptions and potential delays in product availability.
- The company has relatively high debt levels, which can limit flexibility for future investments and acquisitions.
Opportunities
- Expanding into emerging markets can provide Bristol-Myers Squibb Co with new growth opportunities, as these markets have significant unmet healthcare needs.
- Advancements in technology and data analytics present an opportunity for the company to enhance research and improve personalized medicine, creating competitive advantages.
- Mergers or acquisitions with complementary businesses can strengthen Bristol-Myers Squibb Co's market position and diversify its product offerings.
Threats
- Intense competition in the pharmaceutical industry poses a threat to Bristol-Myers Squibb Co's market share and pricing power.
- Regulatory challenges and the increasing complexity of obtaining drug approvals may hinder the company's ability to bring new products to market.
- Changing healthcare policies and pricing pressures can impact the profitability and pricing strategies of Bristol-Myers Squibb Co.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.